Precipio, Inc. (NASDAQ:PRPO – Get Free Report) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 1,200 shares, a decline of 14.3% from the May 31st total of 1,400 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 4,200 shares, the days-to-cover ratio is currently 0.3 days.
Precipio Trading Up 3.7 %
Shares of NASDAQ PRPO traded up $0.19 during trading on Monday, reaching $5.38. The stock had a trading volume of 1,490 shares, compared to its average volume of 5,452. Precipio has a fifty-two week low of $4.65 and a fifty-two week high of $8.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.62 and a current ratio of 0.78. The business’s 50-day moving average price is $5.74 and its 200-day moving average price is $6.13. The company has a market cap of $7.91 million, a P/E ratio of -1.57 and a beta of 1.41.
Precipio (NASDAQ:PRPO – Get Free Report) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($1.46) EPS for the quarter. Precipio had a negative return on equity of 46.12% and a negative net margin of 31.00%. The company had revenue of $3.43 million for the quarter.
About Precipio
Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
Read More
- Five stocks we like better than Precipio
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Healthcare Dividend Stocks to Buy
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Stock Market Upgrades: What Are They?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.